PE20221314A1 - Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro - Google Patents
Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puroInfo
- Publication number
- PE20221314A1 PE20221314A1 PE2022000441A PE2022000441A PE20221314A1 PE 20221314 A1 PE20221314 A1 PE 20221314A1 PE 2022000441 A PE2022000441 A PE 2022000441A PE 2022000441 A PE2022000441 A PE 2022000441A PE 20221314 A1 PE20221314 A1 PE 20221314A1
- Authority
- PE
- Peru
- Prior art keywords
- methods
- dosage forms
- enantiomerically enriched
- bupropion
- pure bupropion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2019/052210 WO2020061486A2 (en) | 2018-09-20 | 2019-09-20 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US202062971174P | 2020-02-06 | 2020-02-06 | |
US202062978626P | 2020-02-19 | 2020-02-19 | |
US202062992060P | 2020-03-19 | 2020-03-19 | |
US16/830,637 US20200222339A1 (en) | 2018-09-20 | 2020-03-26 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US16/907,691 US11433035B2 (en) | 2018-09-20 | 2020-06-22 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
PCT/US2020/046755 WO2021055124A1 (en) | 2019-09-20 | 2020-08-18 | Dosage forms and methods for enantiomerically enriched or pure bupropion |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20221314A1 true PE20221314A1 (es) | 2022-09-07 |
Family
ID=74884634
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2022000441A PE20221314A1 (es) | 2019-09-20 | 2020-08-18 | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP4031121A4 (ko) |
JP (2) | JP2022549192A (ko) |
KR (1) | KR20220066930A (ko) |
CN (1) | CN114423417A (ko) |
AU (2) | AU2020349419B2 (ko) |
BR (1) | BR112022005045A2 (ko) |
CA (1) | CA3154718A1 (ko) |
CO (1) | CO2022003126A2 (ko) |
CR (1) | CR20220119A (ko) |
EC (1) | ECSP22030119A (ko) |
IL (1) | IL291514A (ko) |
MX (1) | MX2022003346A (ko) |
PE (1) | PE20221314A1 (ko) |
WO (1) | WO2021055124A1 (ko) |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999038502A1 (en) * | 1998-01-29 | 1999-08-05 | Sepracor Inc. | Pharmaceutical uses of optically pure (+)-bupropion |
US6150420A (en) * | 1998-06-01 | 2000-11-21 | Theramax, Inc. | Method for enhanced brain delivery of bupropion |
US20190216800A1 (en) * | 2013-11-05 | 2019-07-18 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
MX2013014166A (es) * | 2013-12-03 | 2015-06-10 | Inst De Investigacion En Quimica Aplic S A De C V | Enantiomeros activos y sus sales para el tratamiento de la obesidad. |
US9732031B2 (en) * | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
CR20200415A (es) * | 2018-02-23 | 2021-02-03 | Axsome Therapeutics Inc | Formas y mètodos de dosis para bupropión enantioméricamente enriquecido o puro |
-
2020
- 2020-08-18 MX MX2022003346A patent/MX2022003346A/es unknown
- 2020-08-18 CA CA3154718A patent/CA3154718A1/en active Pending
- 2020-08-18 PE PE2022000441A patent/PE20221314A1/es unknown
- 2020-08-18 CN CN202080065520.4A patent/CN114423417A/zh active Pending
- 2020-08-18 EP EP20866164.5A patent/EP4031121A4/en active Pending
- 2020-08-18 CR CR20220119A patent/CR20220119A/es unknown
- 2020-08-18 BR BR112022005045A patent/BR112022005045A2/pt unknown
- 2020-08-18 JP JP2022517743A patent/JP2022549192A/ja active Pending
- 2020-08-18 WO PCT/US2020/046755 patent/WO2021055124A1/en unknown
- 2020-08-18 AU AU2020349419A patent/AU2020349419B2/en active Active
- 2020-08-18 KR KR1020227013095A patent/KR20220066930A/ko active Search and Examination
-
2022
- 2022-03-18 CO CONC2022/0003126A patent/CO2022003126A2/es unknown
- 2022-03-20 IL IL291514A patent/IL291514A/en unknown
- 2022-04-13 EC ECSENADI202230119A patent/ECSP22030119A/es unknown
-
2024
- 2024-01-05 AU AU2024200081A patent/AU2024200081A1/en active Pending
- 2024-02-22 JP JP2024025971A patent/JP2024059812A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL291514A (en) | 2022-05-01 |
EP4031121A1 (en) | 2022-07-27 |
AU2024200081A1 (en) | 2024-01-25 |
JP2024059812A (ja) | 2024-05-01 |
JP2022549192A (ja) | 2022-11-24 |
AU2020349419B2 (en) | 2023-11-02 |
CO2022003126A2 (es) | 2022-04-19 |
ECSP22030119A (es) | 2022-05-31 |
CR20220119A (es) | 2022-06-22 |
KR20220066930A (ko) | 2022-05-24 |
EP4031121A4 (en) | 2022-11-30 |
BR112022005045A2 (pt) | 2022-07-05 |
CN114423417A (zh) | 2022-04-29 |
MX2022003346A (es) | 2022-04-11 |
CA3154718A1 (en) | 2021-03-25 |
WO2021055124A1 (en) | 2021-03-25 |
AU2020349419A1 (en) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021001810A1 (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
CL2019003924A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485). | |
AR048833A1 (es) | Procedimiento para el tratamiento de trastornos premenstruales y otros trastornos sexuales femeninos | |
CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
WO2020061486A3 (en) | Dosage forms and methods for enantiomerically enriched or pure bupropion | |
MX2018003778A (es) | Ferula para el cuidado bucal. | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
MX2021002322A (es) | Nuevos metodos. | |
MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
NI202000056A (es) | Formas y métodos de dosis para bupropión enantioméricamente enriquecido o puro | |
PE20211199A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
CO2022008001A2 (es) | Métodos para el tratamiento de trastornos depresivos | |
UY38308A (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
NO20082672L (no) | Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon | |
PE20221314A1 (es) | Formas de dosificacion y metodos para bupropion enantiomericamente enriquecido o puro | |
CO6470875A2 (es) | Un compuesto para usar en la prevención y tratamiento de enfermedades cardiovasculares | |
EA202192118A1 (ru) | Фармацевтическая композиция, содержащая ацетаминофен и ибупрофен | |
CL2023000764A1 (es) | Formas farmacéuticas multipartículas que comprenden deutetrabenazina | |
MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
PE20210370A1 (es) | Metodos para modular los niveles de plasma de metabolitos de tetrabenazina utilizando bupropion | |
AR109760A1 (es) | Composiciones y métodos para tratar el mal de alzheimer y la enfermedad de parkinson | |
PL425832A1 (pl) | Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera | |
UA117043U (uk) | Спосіб лікування хронічного періодонтиту |